Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Ionis Pharmaceuticals (NASDAQ:IONS) and maintained a $60 price target.
August 02, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Ionis Pharmaceuticals and maintained a $60 price target.
The reiteration of a Buy rating and the maintenance of a $60 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100